glp-1 eligibility is everywhere right now — but is it actually right for YOU? Before starting any medication, it's important to understand: ✔️ What GLP-1 really does ✔️ Who qualifies medically ✔️ Who Who Qualifies for the Medicare

After 68 weeks, participants receiving a 2.4 mg weekly semaglutide dose experienced a 49% reduction in C-reactive protein (CRP), while those on a 1 mg weekly dose saw a 42% reduction compared to placebo

Signs of B12 Deficiency During GLP-1/GIP Treatment Recognising B12 deficiency can be challenging because symptoms often develop gradually and may be non-specific , particularly in patients managing diabetes or obesity who may attribute these symptoms to their underlying conditions or weight loss efforts

2011 March 2

Four studies (50%) were Phase 4 trials, which typically emphasize safety surveillance post-market approval, indicating a focus on long-term safety and efficacy in real-world settings